Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mach7 Technologies ( (AU:M7T) ) has issued an update.
Mach7 Technologies reported a strong financial performance in the third quarter of FY25, with a Contracted Annual Recurring Revenue (CARR) of A$30.8M and an ARR run rate of A$24.4M. The company achieved sales orders totaling A$5.1M for the quarter and A$21.3M for the nine months ending March 31, 2025. Operating cash flow was positive, and the company maintained a cash reserve of A$24.9M with no debt. Significant cost-saving initiatives are expected to result in annualized savings of A$2M-3M. The company also commenced an on-market share buy-back program and announced a CEO transition, with Teri Thomas set to take over as Managing Director & CEO on July 1, 2025. These developments underscore Mach7’s strategic focus on customer intimacy and its ‘land and expand’ model, positioning the company for continued growth and shareholder value maximization.
More about Mach7 Technologies
Mach7 Technologies Limited is a company specializing in innovative medical imaging software solutions. It focuses on providing advanced imaging solutions to healthcare providers, enhancing their ability to manage and interpret medical images effectively.
Technical Sentiment Signal: Buy
Current Market Cap: $50.04M
For detailed information about M7T stock, go to TipRanks’ Stock Analysis page.